Related Experiment Video
Updated: May 24, 2025

08:07
Differentiation of the SH-SY5Y Human Neuroblastoma Cell Line
Published on: February 17, 2016
71.3K
Lack of efficacy of sofosbuvir in Human Pegivirus associated neurological disorders
V Pourcher1, M Boudot de La Motte2, M Touat3
1Infectious Diseases Department, Pierre-Louis Institute of Epidemiology and Public Health (iPLESP), Inserm U1136, Pitié-Salpêtrière Hospital, AP-HP, Sorbonne University, Paris, France.
Revue Neurologique
|February 28, 2025
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Antiepileptic Drugs: Potassium Channel Activators
140
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
140
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
209
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
209

